Phaseline

Targets › PLN

PLN (Phospholamban): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Nov 2027.

Reversibly inhibits the activity of ATP2A2/SERCA2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+). Binds preferentially to the ATP-bound E1 conformational form of ATP2A2 which predominates at low Ca(2+) concentrations during the diastolic phase of the cardiac cycle (By similarity). (UniProt, P26678)

Open in Phaseline: the race on PLN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaAZD4063
Phospholamban (PLN) inhibitor targeting R14del mutation
PLNPhase 1Dilated CardiomyopathyNov 2027

Conditions

Dilated Cardiomyopathy (1)

Modalities

small molecule (1)

Companies

AstraZeneca (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.